Get the Stockscreener App
1.63
1.24%
0.02
Lexicon Pharmaceuticals Inc stock is traded at $1.63, with a volume of 2.44M.
It is up +1.24% in the last 24 hours and up +28.35% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.61
Open:
$1.625
24h Volume:
2.44M
Relative Volume:
1.00
Market Cap:
$681.12M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-2.0375
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
+8.67%
1M Performance:
+28.35%
6M Performance:
+52.34%
1Y Performance:
+401.85%
1-Day Range:
$1.57
$1.66
1-Week Range:
$1.42
$1.66
52-Week Range:
$0.305
$1.83
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.63 | 672.76M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Exploring Lexicon Pharmaceuticals's Earnings Expectations - Benzinga
LXRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ACSL5 emerges as obesity treatment target, Lexicon Pharmaceuticals outlines - Traders Union
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences - The Manila Times
Lexicon Pharma plans Miami fireside chat, 3 investor events in March - Stock Titan
Lexicon Pharmaceuticals (LXRX) SVP converts RSUs, withholds shares for taxes - Stock Titan
Lexicon Pharmaceuticals (LXRX) SVP converts RSUs, withholds shares for tax - Stock Titan
Lexicon Pharmaceuticals (LXRX) CMO reports RSU vesting and tax share withholding - Stock Titan
Lexicon (NASDAQ: LXRX) SVP nets shares after RSU vesting on Feb 28 - Stock Titan
Executive at Lexicon (NASDAQ: LXRX) settles tax via share withholding - Stock Titan
Lexicon (NASDAQ: LXRX) SVP exercises RSUs and withholds shares for taxes - Stock Titan
Lexicon Pharmaceuticals (LXRX) CFO logs RSU conversion and tax share withholding - Stock Titan
Lexicon (LXRX) CEO Exton exercises RSUs and withholds shares for taxes - Stock Titan
LXRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
LXRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Lexicon Pharmaceuticals director Debbane buys $2980 in shares - Investing.com India
Lexicon Pharmaceuticals director Debbane buys $2980 in shares By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) director adds shares in open-market stock purchase - Stock Titan
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026 - Caledonian Record
Lexicon Pharma plans Mar. 5 webcast on Q4 results, business update - Stock Titan
Lexicon Pharmaceuticals (LXRX) Projected to Post Earnings on Thursday - MarketBeat
Lexicon Pharma spikes after insider buy - MSN
Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Raymond Debbane Acquires 100,000 Shares - MarketBeat
Lexicon Pharmaceuticals pushes for new treatments in hypertrophic cardiomyopathy community - Traders Union
Lexicon Pharmaceuticals director Debbane buys $147,000 in stock - Investing.com Australia
Director buys 100K Lexicon (LXRX) shares at $1.47 in market trade - Stock Titan
Q1 2025 Lexicon Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Lexicon Pharmaceuticals Achieves 107.99% Annual Return, Establishing It as a Multibagger Stock - Markets Mojo
Aug Retail: Is DXC Technology Company forming a double bottom2025 Dividend Review & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Raymond Debbane buys Lexicon Pharmaceuticals (LXRX) shares By Investing.com - Investing.com Australia
Raymond Debbane buys Lexicon Pharmaceuticals (LXRX) shares - Investing.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Buys $72,000.00 in Stock - MarketBeat
Insider Buying: Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Purchases 100,000 Shares of Stock - MarketBeat
Lexicon Pharmaceuticals (LXRX) director buys 150,000 common shares - Stock Titan
Analysts Set Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Price Target at $3.23 - Defense World
How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting With Fine Tuned Targets And Trials - Yahoo Finance
What is Lexicon Pharmaceuticals Inc.’s valuation compared to sectorEarnings Growth Summary & Weekly Watchlist for Consistent Profits - mfd.ru
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Artal Participations boosts Lexicon (NASDAQ: LXRX) stake with Series B preferred buy - Stock Titan
Lexicon Pharmaceuticals (LXRX) Sees Insider Buying Boost - GuruFocus
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap UpHere's What Happened - MarketBeat
Lexicon Pharma stock spikes after insider buy (LXRX:NASDAQ) - Seeking Alpha
GSA Capital Partners LLP Sells 1,627,753 Shares of Lexicon Pharmaceuticals, Inc. $LXRX - MarketBeat
Lexicon (NASDAQ: LXRX) CFO receives new RSU and stock option grants - Stock Titan
Lexicon Pharma spikes after FDA feedback on pain drug - MSN
How rising interest rates impact Lexicon Pharmaceuticals Inc. stockQuarterly Profit Report & Weekly Setup with High ROI Potential - mfd.ru
LXRX PE Ratio & Valuation, Is LXRX Overvalued - Intellectia AI
LXRX Should I Buy - Intellectia AI
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Sentiment Recap: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteriaTrade Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Lexicon Pharmaceuticals completes $100 million stock offering By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):